Core Viewpoint - Baiyunshan (600332.SH) announced that its wholly-owned subsidiary, Zhongyi Pharmaceutical, has received a registration certificate for the traditional medicine An Gong Niu Huang Wan from the Vietnam Ministry of Health, which will be sold in Vietnam through an authorized local company [1] Group 1 - The registration certificate allows Zhongyi Pharmaceutical to expand its business in the Vietnamese market [1] - The impact on the company's current performance is not significant [1] - Sales of pharmaceutical products are subject to market environment changes, indicating potential uncertainties [1]

Core Viewpoint - The company has received a registration certificate for its product, An Gong Niu Huang Wan, from the Traditional Medicine Management Bureau of the Vietnamese Ministry of Health, indicating a significant step in expanding its market presence in Vietnam [1] Group 1: Product Registration - The full subsidiary, Guangzhou Baiyunshan Zhongyi Pharmaceutical Co., Ltd., submitted the drug registration application for An Gong Niu Huang Wan on June 20, 2024 [1] - The product is indicated for clearing heat and detoxifying, as well as calming and opening the orifices [1] Group 2: Financial Performance - The projected sales revenue for An Gong Niu Huang Wan in 2024 is estimated at RMB 156 million [1] - The company has invested approximately RMB 32.7981 million in research and development for this product (unaudited) [1]

Core Viewpoint - Alliance Healthcare Asia Pacific Limited has agreed to transfer its entire 11.04% stake in Nanjing Pharmaceutical to Guangzhou Guangyao Phase II Fund for a total consideration of approximately RMB 748.81 million at a price of RMB 5.18 per share [2][8] Group 1: Share Transfer Details - The share transfer involves 144,557,431 shares, which represents 11.04% of the total share capital of Nanjing Pharmaceutical [2][8] - Following the completion of the transfer, Alliance Healthcare will no longer hold any shares in the company, while Guangzhou Guangyao Phase II Fund will hold the entire 11.04% stake [2][8] Group 2: Strategic Investment Agreement - On September 26, 2025, Nanjing Pharmaceutical's board approved a strategic investment agreement with Guangzhou Baiyunshan Pharmaceutical Group and Guangzhou Guangyao Phase II Fund [6][7] - The agreement aims to establish a long-term strategic partnership based on principles of mutual benefit, resource sharing, and innovation [7] Group 3: Lock-up Commitment - Guangzhou Guangyao Phase II Fund has committed not to transfer the acquired shares for 18 months following the registration of the share transfer, with certain exceptions [3][8] - This commitment includes any shares derived from stock dividends or capital increases during the lock-up period [3][8] Group 4: Regulatory Compliance - The company has disclosed the necessary reports and announcements regarding the share transfer and strategic investment agreement in accordance with regulatory requirements [3][9] - The revised simplified equity change report has been prepared to reflect the updated lock-up commitment [3][9]

Group 1 - The article highlights the upcoming voting deadline for the annual selection of commercial vehicles, which is set for November 17 at 14:00 [2] - Yuchai showcased multiple technical routes and comprehensive power solutions at the Wuhan Commercial Vehicle Exhibition [6] - Hongyan made a strong comeback with the debut of the KX pure electric version, emphasizing extreme lightweight design [6] Group 2 - SANY Heavy Truck has achieved the highest market share in South China, with its direct service model providing significant benefits to customers [6] - Quan Chai has canceled its wholly-owned subsidiary, indicating potential restructuring or strategic shifts [6] - Skyworth Auto secured a significant contract worth 24 million yuan for a bus project, showcasing its competitive positioning in the market [6]

Core Insights - The official launch of WALOVI International Cans in Malaysia marks a significant milestone for Wang Laoji, following its entry into the Singapore market, indicating a new phase in its expansion within the ASEAN market [1][19] - The event was part of the 2025 Fortune Innovation Forum, which gathered over 300 global business leaders and policymakers, emphasizing the importance of the forum as a platform for exploring new opportunities in a post-globalization world [5][14] Company Strategy - Wang Laoji's product line includes four flavors: classic, sparkling, sugar-free, and original, designed to meet local consumer demands and reflect Eastern aesthetics [7][12] - The brand aims to convey its "natural health philosophy" and has achieved significant recognition in the Malaysian market, as evidenced by the positive feedback from Malaysia's Deputy Prime Minister [10][12] Market Potential - Malaysia, with a population exceeding 33 million and a notable GDP per capita, presents a substantial consumer market for health beverages, driven by local climate and cultural factors [14][16] - The presence of a significant Chinese population (22.6%) in Malaysia enhances the acceptance of natural plant-based beverages, providing a strategic advantage for Wang Laoji [14] Trade Relations - The strengthening of economic ties between China and Malaysia, with bilateral trade reaching a historical high of $212 billion in 2024, supports Wang Laoji's localized development efforts [16] - The implementation of the RCEP trade agreement facilitates more efficient market entry for Wang Laoji in Southeast Asia [16] Global Expansion - Wang Laoji has expanded its overseas market presence by over 6.5 times in the past decade, with a compound annual growth rate exceeding 25%, covering over 100 countries [19][20] - The brand's global strategy has shifted from merely exporting products to a comprehensive approach that includes supply chain and brand globalization, establishing a robust foundation for its Southeast Asian market penetration [19][20]

1 本次交易尚需上海证券交易所进行合规性确认后方能办理股份过户 等手续，最终能否实施并完成交易尚存在不确定性。本公司将持续关注本 次交易进展，并严格按照有关法律、法规要求及时履行信息披露义务。敬 请广大投资者理性投资，注意投资风险。 证券代码：600332 证券简称：白云山 公告编号：2025－078 广州白云山医药集团股份有限公司 关于广州广药二期基金股权投资合伙企业（有限合伙） 收购南京医药股份有限公司 11.04%股权的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 一、本次交易的基本情况 2025 年 9 月 26 日，广州白云山医药集团股份有限公司（"本公司"） 召开第九届董事会第二十九次会议，审议通过了《关于广州广药二期基金 股权投资合伙企业（有限合伙）收购南京医药股份有限公司 11.04%股份 的议案》。本公司附属企业广州广药二期基金股权投资合伙企业（有限合 伙）（"广药二期基金"）拟以自有资金通过协议转让方式收购 Alliance Healthcare Asia Pacific Limited（"AH ...

海外監管公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出的。 茲刊載廣州白雲山醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(www.sse.com.cn)刊登的 本公司關於廣州廣藥二期基金股權投資合夥企業（有限合夥）收購南京醫藥股份有限公司11.04%股權 的進展公告之中文全文，僅供參考。 廣州白雲山醫藥集團股份有限公司 董事會 中國廣州，2025年11月17日 於本公告日，本公司董事會成員包括執行董事李小軍先生、陳傑輝先生、程寧女士、程洪進先生、 唐和平先生與黎洪先生，及獨立非執行董事陳亞進先生、黃民先生、黃龍德先生與孫寶清女士。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对 其内容的真实性、准确性和完整性承担法律责任。 一、本次交易的基本情况 2025 年 9 月 26 日，广州白云山医药集团股份有限公司（"本公司"） 召开 ...

格隆汇11月17日丨南京医药(600713.SH)公布，近日，公司收到广药二期基金《告知函》，广药二期基 金已取得其国资主管单位广州医药集团有限公司出具的《广药集团关于广州广药二期基金股权投资合伙 企业（有限合伙）受让南京医药股份有限公司11.04%股份的批复》，同意广药二期基金通过协议转让 方式受让Alliance Healthcare持有的南京医药1.45亿股非限售股份，占《战略投资协议》签署之日南京医 药总股本的11.04%，转让价款为人民币7.49亿元。 广药二期基金同时出具《承诺函》，承诺自目标股份过户登记至广药二期基金名下之日起18个月内，广 药二期基金不会对外转让目标股份（不包括转让给白云山控制的其他主体）。在前述期限内，因南京医 药送股、转增股本等事项而衍生、增加的股份，亦遵守前述股份锁定安排。 ...

Core Insights - The outdoor sports sector, particularly the sales of jackets, has seen significant growth during the recent "Double 11" shopping event, with jackets ranking high on sales charts across e-commerce platforms [2] - The company BERSHIHE has submitted a listing application to the Hong Kong Stock Exchange, aiming to become the "first stock of high-performance outdoor lifestyle in China" [2] - BERSHIHE's sales of jackets are projected to reach 3.8 million units from 2022 to 2024, with a compound annual growth rate (CAGR) of 122.2% [2] Company Overview - BERSHIHE's primary products include jackets and footwear, with jackets contributing over 80% of revenue from 2022 to 2024 [3] - The company operates primarily through a direct-to-consumer (DTC) multi-channel sales model [2][3] - BERSHIHE's revenue for 2022, 2023, and 2024 is reported at 378 million, 908 million, and 1.766 billion respectively, with net profits of 24.3 million, 152 million, and 283 million [7] Market Position - The outdoor apparel market is experiencing a 16% annual compound growth rate, indicating a robust growth trajectory for brands like BERSHIHE [2] - BERSHIHE's market share in 2024 is estimated at 5.2%, indicating room for growth compared to competitors like ANTA and other established brands [5] - The company has a low asset-liability ratio of 36% and a gross margin of 59.6%, which are favorable compared to industry standards [8] Sales Channels - BERSHIHE heavily relies on online sales, with DTC sales expected to exceed 1.35 billion in 2024, while offline sales are only projected at 169 million, accounting for 9.6% of total revenue [8] - The company has been expanding its offline presence but has only opened 146 stores by the end of 2024, falling short of its initial target of 500 stores [9] Marketing and Branding - BERSHIHE's marketing expenses have increased significantly, from 120 million in 2022 to 587 million in 2024, representing over one-third of total revenue [10] - The company is exploring high-end product lines to enhance brand perception, with new products priced comparably to premium brands like Arc'teryx [10][11] - The challenge remains for BERSHIHE to balance cost-effectiveness with the establishment of a premium brand image [11]

Core Insights - The 2025 Fortune Innovation Forum will be held in Kuala Lumpur, Malaysia, on November 17-18, gathering over 300 global business leaders, investment elites, and policymakers to explore new strategic paradigms in a rapidly changing world [2][5]. Group 1: Key Themes - The forum will address geopolitical tensions, protectionism, and the rapid evolution of artificial intelligence, which are reshaping traditional alliances and market foundations [2]. - The theme "Navigating Change: Winning Strategies in a Post-Globalized World" will focus on creating new opportunities in areas such as energy transition, sustainable development, and food security [2]. - Discussions will include the impact of technological advancements, digital revolutions, and artificial intelligence on business practices and workforce dynamics [4]. Group 2: Future Outlook - Malaysia's Johor state is projected to become a major data center hub in the next five years, potentially surpassing Northern Virginia in the U.S. [5]. - The forum aims to highlight Malaysia's growth story and unique strategic opportunities, positioning it as a focal point for global attention [5].